You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (360Dx) – Citing the technology's ability to detect sepsis in blood samples within hours, H.C. Wainwright today initiated coverage of T2 Biosystems with a Buy rating, and a 12-month price target of $8 for the company's shares.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.